Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism

Jawed Fareed1,2*, Cafer Adiguzel1,2,3 and Indermohan Thethi4

Abstract

Background: The prevention of venous thromboembolism has been identified as a leading priority in hospital safety. Recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include unfractionated heparin, low-molecular-weight heparins and fondaparinux. Prescribing decisions in venous thromboembolism management may seem complex due to the large range of clinical indications and patient types, and the range of anticoagulants available.

Methods: MEDLINE and EMBASE databases were searched to identify relevant original articles.

Results: Low-molecular-weight heparins have nearly replaced unfractionated heparin as the gold standard antithrombotic agent. Low-molecular-weight heparins currently available in the US are enoxaparin, dalteparin, and tinzaparin. Each low-molecular-weight heparin is a distinct pharmacological entity with different licensed indications and available clinical evidence. Enoxaparin is the only low-molecular-weight heparin that is licensed for both venous thromboembolism prophylaxis and treatment. Enoxaparin also has the largest body of clinical evidence supporting its use across the spectrum of venous thromboembolism management and has been used as the reference standard comparator anticoagulant in trials of new anticoagulants. As well as novel oral anticoagulant agents, biosimilar and/or generic low-molecular-weight heparins are now commercially available. Despite similar anticoagulant properties, studies report differences between the branded and biosimilar and/or generic agents and further clinical studies are required to support the use of biosimilar low-molecular-weight heparins. The newer parenteral anticoagulant, fondaparinux, is now also licensed for venous thromboembolism prophylaxis in surgical patients and the treatment of acute deep-vein thrombosis; clinical experience with this anticoagulant is expanding.

Conclusions: Parenteral anticoagulants should be prescribed in accordance with recommended dose regimens for each clinical indication, based on the available clinical evidence for each agent to assure optimal safety and efficacy.

Introduction

Venous thromboembolism (VTE) is a common disease that occurs in hospitalized surgical and medical patients and in the community [1]. In 2003, over 12 million medical and surgical patients in the Nationwide Inpatient Sample, comprising 31% of all US hospital discharges for that year, were at risk of VTE and warranted thromboprophylaxis [2]. The risk of VTE can persist for a considerable period of time after the VTE-triggering event, such as surgery, or hospitalization for an acute medical condition [3]. The period of increased thrombotic risk may be sustained by the presence of ongoing risk factors such as malignancy or immobility [1]. In addition, the risk of recurrent VTE is high, with nearly one-third of patients experiencing a recurrent event within 8 years [4]. In patients who do suffer a recurrent VTE requiring rehospitalization, 50% of these events occur in the first 3 months after their initial deep-vein thrombosis (DVT) or pulmonary embolism (PE) [5]. After a VTE event, upto one-third of patients may suffer...
from the post-thrombotic syndrome, which causes long-term morbidity due to leg pain, swelling, and the effects of vascular insufficiency [4].

Effective prevention of VTE has therefore been identified by the Agency for Healthcare Research and Quality as the leading priority in hospital safety practices. Hospitals have the potential to reduce the clinical and economic burden of VTE by implementing hospital-wide protocols for the prevention and treatment of VTE. Several guidelines are available such as those regularly updated by the American College of Chest Physicians (ACCP) and the International Union of Angiology (IUA) [6-8], as well as specialty-based VTE guidelines.

A number of parenteral antithrombotic regimens are available and recommended for the prevention and treatment of VTE, including unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs; enoxaparin, dalteparin, tinzaparin), and selective anti-Xa inhibitors (fondaparinux), as well as oral vitamin K antagonists (warfarin). Due to the number and complexity of indications in VTE management, the choice of antithrombotic agent can appear complicated. In particular, differentiating between the parenteral antithrombotics can be confusing as expert guidelines on VTE usually recommend one of a number of options and ‘a LMWH’ rather than specifying which LMWH to prescribe. However, LMWHs are distinct pharmacological agents and not clinically interchangeable, as stated by regulatory authorities including the US Food and Drug Administration (FDA), European Medicines Agency (EMEA), World Health Organization, ACCP, American Heart Association, and American College of Cardiology [6,7,9-12]. Therefore, when prescribing a LMWH for either the prevention or treatment of VTE, the clinical evidence for each agent must be reviewed. This review aims to assist this decision-making process by analyzing points of differentiation between each of the parenteral antithrombotic agents recommended in current VTE management guidelines.

**Currently available parenteral anticoagulants for VTE prevention and treatment**

UFH has long been used as an anticoagulant in the prevention and treatment of VTE. Prophylaxis with anticoagulants is effective in reducing the incidence of VTE and in treating acute VTE [6,8,13], but is inherently associated with a risk of bleeding complications. UFH use is also limited by the need for regular coagulation monitoring. Over the last 10 years, UFH has been replaced as the reference standard anticoagulant in VTE management by the LMWHs. Three LMWHs are currently available in the USA: enoxaparin, dalteparin, and tinzaparin. These LMWHs are individual pharmacological entities and have different FDA-licensed indications and dosing regimens. More recently, the synthetic pentasaccharide fondaparinux has been developed and FDA approved.

**Mechanism of action**

Although UFH, LMWHs, and fondaparinux are all indirect anticoagulants and exert their effects through binding to the plasma cofactor antithrombin (AT) and releasing endogenous mediators, a first point of differentiation between UFH, LMWHs, and fondaparinux is their chemical composition and mechanisms of action.

UFH is a heterogeneous mixture of highly sulfated mucopolysaccharides of varying lengths with molecular weights ranging from 3,000 to 30,000 Da (mean 15,000 Da) that has been used as an anticoagulant since the 1950s. However, its mechanism of action was not described until the 1970s. Only about one-third of the heparin molecules contain the pentasaccharide binding sequence required for its anticoagulant effect. By binding to AT, heparin induces a conformational change that facilitates the binding of AT to thrombin and catalyzes the inhibitory action of AT on both thrombin and Factor Xa. Heparin subsequently dissociates from the thrombin/AT complex and can be reutilized [14]. The other high-molecular-weight chains with low anticoagulant properties exhibit protein- and cell-binding effects and contribute to bleeding and other side-effects of UFH, such as thrombocytopenia and osteopenia [14].

In the 1980s, the LMWHs were produced using physical, chemical, or enzymatic depolymerization processes. Each LMWH consists of a heterogeneous mixture of polysaccharide chains with molecular weights ranging from 2,000 to 9,000 Da (mean 4,000-5,500 Da, depending on the LMWH). As with UFH, the LMWHs bind to AT and catalyze the inhibition of Factor Xa but, as the polysaccharide chains are much smaller than those in UFH, the majority of LMWH molecules are too short to bridge AT to thrombin. Accordingly, LMWHs have a much greater inhibitory effect on Factor Xa than on thrombin. Whereas UFH has an anti-Factor Xa to anti-Factor IIa ratio of 1:1, the corresponding ratio for the LMWHs ranges from 2:1 to 14:1. The shorter mucopolysaccharide chains also mean that the LMWHs have reduced cell and plasma protein binding compared to UFH. This translates clinically into a more predictable dose-response effect and a lower potential for LMWHs to induce effects such as heparin-induced thrombocytopenia. Each of the LMWH preparations has a different mixture of polysaccharide units due to the specific depolymerization process used in their manufacture, i.e. enoxaparin by alkaline depolymerization of heparin benzyl ester, dalteparin by nitrous acid depolymerization, and tinzaparin by enzymatic degradation using heparinase. This variation among the LMWHs gives rise to
the different pharmacokinetic and pharmacodynamic profiles of the different LMWH agents [14]. Fondaparinux is a synthetic pentasaccharide with a molecular weight of 1,728 Da containing an AT-binding domain modified from that found in UFH and LMWHs to increase its affinity for AT. Fondaparinux cannot inhibit thrombin and its anticoagulant activity is entirely dependent on its ability to selectively inhibit Factor Xa [15]. Fondaparinux can be differentiated further from the polypharmacologic effects of UFH and LMWHs, as it does not release tissue factor pathway inhibitor [16].

Use of parenteral anticoagulants throughout the continuum of VTE care
Translation of the differences in chemical profiles of the parenteral anticoagulants to their clinical profile is not straightforward. Parenteral anticoagulants have different FDA-approved indications for VTE, and there are differences in the supporting clinical evidence. Table 1 shows that, of the LMWHs, enoxaparin is licensed for the broadest range of VTE indications, encompassing both the prevention and treatment of VTE, based on the strength and depth of supporting clinical evidence. Tinzaparin is licensed for the treatment of VTE but not for VTE prophylaxis in any patient group, while dalteparin is licensed for VTE prevention but not for VTE treatment other than long-term treatment in cancer patients. Fondaparinux has received FDA approval for VTE prevention after orthopedic and abdominal surgery and for treatment of VTE (Table 1).

In-hospital VTE prophylaxis
Meta-analyses of randomized controlled clinical studies have shown that the LMWHs are at least as safe and effective as UFH in preventing VTE in both medical and surgical inpatients [16,17]. In general surgery, a meta-analysis of 51 studies involving more than 48,000 patients reported that prophylaxis with LMWHs was associated with a significant reduction in the incidence of clinical VTE compared to prophylaxis with UFH (p = 0.049) with a similar rate of major bleeding complications (p = 0.16) [18]. In hospitalized medical patients, a meta-analysis of nine trials including data from 4,669 patients demonstrated that the LMWHs and UFH were both similarly effective in reducing the incidence of VTE, but LMWHs were associated with 52% fewer bleeding complications than with UFH (p = 0.049) [17].

Meta-analyses are valuable to confirm the favorable risk-to-benefit profile associated with LMWH prophylaxis but they include data from trials of various LMWH preparations and cannot be used to support prescribing decisions for an individual LMWH. For this reason, the efficacy and safety data from the clinical studies for each LMWH need to be reviewed. Table 2 summarizes the key published data in the prevention of VTE for each of the LMWHs currently available in the USA and fondaparinux [13,19-40].

Enoxaparin has been evaluated in multiple randomized controlled trials in different patient populations and against different comparators. In patients undergoing hip replacement surgery, enoxaparin 30 mg twice daily (bid) was associated with a lower incidence of symptomatic or asymptomatic VTE versus placebo (12% vs 42%; p = 0.0007) with low rates of major bleeding (2% and 4%, respectively) [19]. Several trials comparing enoxaparin 40 mg once daily or 30 mg bid with UFH bid or three times daily (tid) in this patient population demonstrated at least similar incidence rates of VTE and major bleeding [20,21]. In one study, enoxaparin 30 mg bid was associated with a lower rate of VTE (5% vs 12%; p = 0.03) and no increased bleeding (4% vs 6%) compared with UFH [21]. Compared with warfarin, enoxaparin 30 mg bid was associated with a lower incidence of symptomatic VTE during hospitalization (1.1% vs 0.3%, respectively; p = 0.0083) with major bleeding rates of 0.3% and 0.6% [22]. In trials in patients undergoing knee replacement surgery, there was a consistently

Table 1 Food and Drug Administration-approved indications of parenteral anticoagulants available for the treatment and prevention of venous thromboembolism in the US

| Indication                           | Enoxaparin | Dalteparin | Tinzaparin | Fondaparinux |
|--------------------------------------|------------|------------|------------|--------------|
| Prophylaxis                          |            |            |            |              |
| Hip replacement surgery              | Yes        | Yes        | No         | Yes          |
| Knee replacement surgery             | Yes        | No         | No         | Yes          |
| Hip fracture surgery                 | No         | No         | Yes        | No           |
| Abdominal surgery                    | Yes        | Yes        | No         | No           |
| Acutely ill medical patients         | Yes        | No         | Yes        | No           |
| Treatment                            | Yes        | No         | Yes        | Yes          |
| - Inpatient DVT with/without PE      | - Inpatient DVT with/without PE | - DVT - PE when initial therapy is administered in the hospital |
| - Outpatient DVT without PE          |            |            |            |              |
| Secondary prophylaxis/extended treatment in cancer patients | No         | Yes        | No         | No           |

DVT, deep-vein thrombosis; PE, pulmonary embolism.
Table 2 Clinical evidence from randomized controlled trials for the efficacy and safety of parenteral anticoagulants in the prophylaxis of VTE

| Indication/agent | Ref. | N   | Dose                  | Comparator   | VTE, %          | Major bleeding, % |
|-----------------|------|-----|-----------------------|--------------|-----------------|-------------------|
| Hip replacement surgery |      |     |                       |              |                 |                   |
| Enoxaparin      | [19] | 100 | 30 mg bid             | Placebo      | 12 vs 42 (p = 0.0007) | 2 vs 4            |
|                 | [20] | 665 | 30 mg bid             | UFH bid      | 17.1 vs 19.0     | 3.3 vs 5.7        |
|                 | [21] | 607 | 40 mg once daily      | UFH tid      | 15 vs 12         | 1 vs 6 (p = 0.014) |
|                 |      |     | 30 mg bid             | Placebo      | 5 vs 12 (p = 0.03) | 4 vs 6            |
| Dalteparin      | [22] | 3,011 | 30 mg bid          | Warfarin     | 0.3 vs 1.1* (p = 0.0083) | 0.6 vs 0.3  |
|                 |      |     | 2,500 pre-op and post-op, 5,000 IU once daily | Warfarin | 10.7 vs 24 (p < 0.001) | 2.2 vs 0.4 (p = 0.01) |
|                 |      |     | 2,500 post-op, 5,000 IU once daily | Enoxaparin 40 mg once daily | 13.1 vs 24 (p < 0.001) | 0.8 vs 0.4  |
| Tinzaparin      | [24] | 440 | 4,500 IU              | Enoxaparin 40 mg once daily | 21.7 vs 20.1 | 0.9 vs 1.8        |
| Fondaparinux    | [25] | 2,309 | 2.5 mg once daily     | Enoxaparin 40 mg once daily | 4 vs 9 (p < 0.0001) | 4 vs 3           |
|                 | [26] | 1,584 | 2.5 mg once daily     | Enoxaparin 30 mg bid | 6 vs 8         | 2.0 vs 0.7        |
| Knee replacement surgery |      |     |                       |              |                 |                   |
| Enoxaparin      | [27] | 670 | 30 mg bid             | Warfarin     | 369 vs 51.7 (p = 0.003) | 2.1 vs 1.8          |
|                 | [28] | 349 | 30 mg bid             | Warfarin     | 25.4 vs 45.5 (p = 0.0001) | 5.2 vs 2.3        |
| Fondaparinux    | [29] | 724 | 2.5 mg bid             | Enoxaparin 30 mg bid | 12.5 vs 27.8 (p < 0.001) | 2.1 vs 0.2 (p = 0.006) |
| Hip fracture surgery |      |     |                       |              |                 |                   |
| Fondaparinux    | [30] | 1,250 | 2.5 mg once daily     | Enoxaparin 40 mg once daily | 8.3 vs 19.1 (p < 0.001) | 2.2 vs 2.3       |
| Abdominal surgery |      |     |                       |              |                 |                   |
| Enoxaparin      | [31] | 631 | 40 mg once daily      | UFH tid      | 14.7 vs 18.2     | 4.1 vs 2.9        |
| Dalteparin      | [13] | 3,809 | 2,500 IU              | UFH bid      | 1.0 vs 1.1*      | 3.6 vs 4.8        |
|                 | [32] | 1,957 | 5,000 IU              | Dalteparin 2,500 IU | 66 vs 12.7 (p < 0.001) | 1.3 vs 0.3        |
| Fondaparinux    | [33] | 2,048 | 2.5 mg once daily     | Dalteparin 2,500 pre-op and post-op, 5,000 IU once daily | 4.6 vs 6.1 (p = 0.144) | 3.4 vs 2.4 (p = 0.122) |
| Acutely ill medical inpatients |      |     |                       |              |                 |                   |
| Enoxaparin      | [34] | 866 | 40 mg once daily      | Placebo      | 5.5 vs 14.9 (p < 0.001) | 3.4 vs 2.0       |
|                 | [35] | 959 | 40 mg once daily      | UFH tid      | 0.2 vs 14*       | 0.4 vs 1.5        |
|                 | [36] | 451 | 40 mg once daily      | UFH tid      | 8.4 vs 10.4 (p = 0.015 for equivalence) | 0.3 vs 0.3       |
|                 | [37] | 212 | 40 mg once daily      | UFH 5,000 U tid | 19.7 vs 34.7 (p = 0.044) | 2.8 vs 1.9       |
|                 | [38] | 1,762 | 40 mg once daily     | UFH 5,000 U bid | 10 vs 18 (p = 0.0001) | 1 vs 0 (p = 0.015) |
| Dalteparin      | [39] | 3,706 | 5,000 IU              | Placebo      | 2.77 vs 4.96 (p = 0.0015) | 0.49 vs 0.16 (p = 0.15) |
| Fondaparinux    | [40] | 849  | 2.5 mg once daily     | Placebo      | 5.6 vs 10.5 (p = 0.029) | 0.2 vs 0.2        |

*Incidence of symptomatic VTE diagnosed during hospitalization.

†Intent-to-treat population.

bid, twice daily; tid, three times daily; UFH, unfractionated heparin; VTE, venous thromboembolism.
lower incidence of VTE with enoxaparin 30 mg bid than with warfarin with no significant increase in the rate of major bleeding [27,28]. In patients undergoing abdominal or pelvic surgery for cancer, enoxaparin 40 mg once daily was as effective and safe as UFH administered tid [31]. In acutely ill medical patients, the incidence of symptomatic or non-symptomatic VTE was lower with enoxaparin 40 mg once daily than with placebo (5.5% vs 14.9%; p < 0.001) with no significant increase in major bleeding (3.4% vs 2.0%) [34]. Enoxaparin 40 mg once daily was as safe and effective as UFH 5000U tid [35,36]. In patients with acute ischemic stroke, the risk of symptomatic or asymptomatic VTE with enoxaparin 40 mg once daily was lower compared to that with UFH 5000 U bid (10% vs 18%; p = 0.001), with a similar risk of symptomatic intracranial bleeding (1% vs 1%; p = 0.55) and a higher rate of major extracranial bleeding (1% vs 0; p = 0.015) [38] (Table 2).

Dalteparin has also been evaluated for the prevention of VTE. In patients undergoing hip replacement surgery, dalteparin 5,000 IU once daily was associated with a lower incidence of VTE compared with warfarin (11.9% vs 24.0%; p < 0.001), while major bleeding was higher with preoperative initiation of dalteparin (2.2% vs 0.4%; p = 0.01) but not postoperative initiation (0.8% vs 0.4%) [23]. In abdominal surgery, dalteparin 2,500 IU was as safe and effective as UFH bid [13]. In acutely ill medical patients, the incidence of symptomatic or asymptomatic VTE was lower with dalteparin 5,000 IU versus placebo (2.77% vs 4.96%; p = 0.0015) with no significant increase in major bleeding (4.9% vs 0.16%; p = 0.15) [39]. Few randomized controlled trials have evaluated the off-label use of tinzaparin in the prevention of VTE [24] (Table 2).

Trials with fondaparinux 2.5 mg once daily in hip replacement surgery demonstrated a lower incidence of VTE when compared with enoxaparin 40 mg once daily [25], but an equivalent incidence compared with enoxaparin 30 mg bid [26], while reporting no significant difference in the incidence of major bleeding. In knee replacement surgery, fondaparinux 2.5 mg bid was associated with a lower incidence of asymptomatic or symptomatic VTE compared with enoxaparin 30 mg bid (12.5% vs 27.8%; p < 0.001), at the expense of an increase in major bleeding complications (2.1% vs 0.2%; p = 0.006) [29]. In hip fracture surgery, fondaparinux 2.5 mg once daily was compared with enoxaparin 40 mg once daily, and showed a lower rate of VTE (8.3% vs 19.1%; p < 0.001) with no significant difference in major bleeding rates (2.2% vs 2.3%; p = 1.0) [30]. In a meta-analysis of 4 trials in major orthopedic surgery patients, the incidence of symptomatic or asymptomatic VTE with fondaparinux was lower compared with enoxaparin (6.8% vs 13.7%; p < 0.001) with an increase in major bleeding events (2.7% vs 1.7%; p = 0.008) [41].

Fondaparinux 2.5 mg once daily in patients undergoing abdominal surgery was associated with similar rates of VTE (4.6% vs 6.1%; p = 0.144) and major bleeding (3.4% vs 2.4%; p = 0.122) compared with dalteparin 5,000 IU started preoperatively at a dose of 2,500 IU [33]. In acutely ill medical patients at risk of VTE, fondaparinux was associated with a lower incidence of asymptomatic or symptomatic VTE compared with placebo (5.6% vs 10.5%; p = 0.029) and did not increase major bleeding (0.2% vs 0.2%) [40] (Table 2).

**Extended-duration thromboprophylaxis**

It has been reported that more than two-thirds of all symptomatic VTE events occur in the outpatient setting, predominantly in patients who have recently undergone surgery or been hospitalized for medical illness [3]. In fact, 47% and 76% of all clinical VTE events related to hip or knee replacement, respectively, occur post-discharge [42]. Currently, both the ACCP and IUA guidelines recommend prophylaxis extended beyond hospitalization to up to 35 days in specific patient groups, such as patients undergoing major elective orthopedic surgical procedures or major surgery for cancer [6,8].

The majority of the available clinical evidence for the use of LMWHs as extended-duration prophylaxis is with enoxaparin. In orthopedic surgery, three randomized, double-blind placebo-controlled trials have shown that a lower incidence of VTE can be achieved by extending the duration of prophylaxis with enoxaparin to 4 weeks postoperatively, without an increasing in the number of bleeding complications or other adverse events [43-45]. Similarly, a double-blind randomized controlled study in patients undergoing major surgery for abdominal or pelvic cancer has shown that 4 weeks of prophylaxis with enoxaparin 40 mg once daily is significantly more effective in reducing VTE than 1 week of enoxaparin prophylaxis (4.8% vs 12.0%; p = 0.02) with no increase in major bleeding (0.8% vs 0.4%; p > 0.99); this benefit was sustained during a 3-month follow-up period [46].

Dalteparin has been evaluated for extended-duration prophylaxis in surgical patients; two double-blind placebo-controlled studies have shown a lower incidence of late VTE with dalteparin in patients undergoing total hip replacement surgery without increasing major bleeding [47,48]. A small study (n = 176) on extended-duration prophylaxis with tinzaparin after general surgery failed to demonstrate a significant difference between 1 and 4 weeks of prophylaxis (VTE incidence 5.2% vs 10%; p = 0.49) and reported similar rates of bleeding (2/58 vs 3/60) [49]. Fonddaparinux has been shown to be effective as extended-duration prophylaxis after major orthopedic surgery in two trials. The placebo-controlled PENTHI-FRA study reported that in patients who had undergone
hip fracture surgery extending the duration of prophylaxis with fondaparinux for 3 weeks was associated with a lower risk of symptomatic VTE (0.3% vs placebo 2.7%; p = 0.02) with an increase in major bleeding complications bordering significance (2.4% vs 0.6%; p = 0.06) [50]. Similarly, 3-5 weeks of extended-duration VTE prophylaxis with fondaparinux was shown to be effective and have a good safety profile after major lower limb surgery in patients with or without indwelling neuraxial or deep peripheral nerve catheters [51].

**Treatment of VTE**

Current ACCP guidelines recommend LMWH, UFH, or fondaparinux for the short-term treatment of objectively confirmed VTE [7]. Treatment with a LMWH given subcutaneously once daily or bid is recommended over UFH, on an outpatient basis if possible, and as an inpatient if necessary [7]. A number of clinical studies [52-57] and a meta-analysis [58] have demonstrated that the LMWHs are superior or non-inferior to UFH in preventing VTE recurrence (pooled relative risk [RR] 0.85, 95% confidence interval [CI]: 0.65-1.12; N = 4,447) and the incidence of bleeding events (pooled RR 0.63, 95% CI: 0.37-1.05; N = 4,447), and superior to UFH in terms of improved survival (pooled RR 0.76, 95% CI: 0.59-0.98; N = 4,033) [58]. The key clinical studies of each of the LMWHs in the treatment of VTE [52-57] are shown in Table 3 [52-57,59-61].

Enoxaparin is the only LMWH currently licensed in the US for outpatient treatment of acute DVT (without PE) in conjunction with oral warfarin (Table 1). A meta-analysis of studies of enoxaparin outpatient treatment including more than 1,500 patients with DVT, with or without PE, reported that enoxaparin is as effective in terms of VTE recurrence, major bleeding, and death as inpatient treatment with UFH [62]. The presence of symptomatic PE does not appear to affect the outcomes of DVT treatment with enoxaparin [62]. Furthermore, enoxaparin continued beyond the initial treatment of DVT offers benefits; an analysis of outpatient treatment of VTE with enoxaparin found that outpatient treatment with a combination of enoxaparin and warfarin was associated with 26% (p < 0.05) fewer hospital readmissions for recurrent DVT or PE compared to patients treated with warfarin alone. This was associated with an overall saving of USD 1,151 per patient in total DVT-treatment-related costs over warfarin monotherapy [63].

Although clinical data are available for dalteparin in the treatment of VTE [53], it is not licensed by the FDA for VTE treatment other than long-term treatment in cancer patients (Table 1). The CLOT trial reported that long-term prophylaxis with dalteparin in patients with cancer and DVT was associated with a significantly lower incidence of VTE recurrence compared to oral anticoagulant therapy with no increase in bleeding complications [64]. Based on the findings of the CLOT trial [64], dalteparin is licensed for extended-duration prophylaxis in patients with cancer as a regimen of anti-Factor Xa 200 IU/kg once daily for 1 month followed by anti-Factor-Xa 150 IU/kg for an additional 5 months.

### Table 3 Evidence from clinical trials of the efficacy and safety of parenteral anticoagulants in the treatment of VTE

| Indication/agent | Ref. | N   | Dose                              | Patients               | Comparator | Recurrent VTE, % | Major bleeding, % |
|------------------|------|-----|-----------------------------------|------------------------|------------|-----------------|-------------------|
| Inpatient VTE treatment |      |     |                                   |                        |            |                 |                   |
| Enoxaparin       | [52] | 900 | 1.5 mg/kg once daily              | DVT                    | IV UFH     | 4.4 vs 4.1*     | 1.7 vs 2.1*       |
|                  |      |     | 1.0 mg/kg bid                     |                        | IV UFH     | 2.9 vs 4.1*     | 1.3 vs 2.1*       |
| Dalteparin       | [53] | 204 | 200 IU/kg once daily              | DVT                    | IV UFH     | 5.0 vs 2.9      | 0 vs 0            |
|                  | [54] | 253 | 200 IU/kg once daily              | DVT                    | IV UFH     | 3.6 vs 1.7      | 0 vs 1.5          |
| Tinzaparin       | THESEE | 612 | 175 IU/kg once daily              | PE                     | IV UFH     | 1.6 vs 1.9*     | 2.0 vs 2.6*       |
| Fondaparinux     | MATISSE [59] | 2,213 | 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) | PE                     | IV UFH     | 3.8 vs 5.0*     | 2.0 vs 2.4*       |
|                  | [60] | 2,205 | 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) | DVT                    | Enoxaparin 1.0 mg/kg bid | 3.9 vs 4.1* | 2.6 vs 2.4* |
| Outpatient treatment |      |     |                                   |                        |            |                 |                   |
| Enoxaparin       | [56] | 500 | 1.0 mg/kg bid                     | DVT                    | IV UFH (inpatient) | 5.3 vs 6.7 | 2.0 vs 1.2       |
|                  | [61] | 298 | 1.5 mg/kg once daily              | DVT                    | IV UFH (inpatient) | 2.7 vs 8.8 (p = 0.026) | 0 vs 2.0       |
| Tinzaparin       | [57] | 505 | 175 IU/kg once daily              | DVT and/or PE          | Dalteparin 200 IU/kg once daily | 3.9 vs 3.6 | 2.0 vs 0.8   |

*Non-inferior.

bid, twice daily; DVT, deep-vein thrombosis; IV, intravenous; PE, pulmonary embolism; UFH, unfractionated heparin; VTE, venous thromboembolism.
Tinzaparin is licensed for the inpatient treatment of DVT with or without PE [51] (Table 1). A study comparing tinzaparin 175 IU once daily with dalteparin 200 IU once daily for outpatient treatment of DVT and/or PE reported no significant difference in the incidence of recurrent VTE or major bleeding between the two LMWHs [57]. Fondaparinux is licensed for the outpatient treatment of DVT, and of PE if initial treatment takes place in the hospital (Table 1). Non-inferiority for VTE recurrence and major bleeding was demonstrated compared to UFH in the treatment of PE [59] and compared to enoxaparin in the treatment of DVT [60].

**Differentiation between branded and biosimilar LMWHs**

Biosimilar versions of enoxaparin have been developed and being marketed as generic equivalents and clinically used in India and South America, and initial regulatory approval of a biosimilar formulation of enoxaparin was granted in Canada [65]. In July 2010, the US FDA approved a generic version of enoxaparin [Sandoz, a division of Novartis group] utilizing the generic drug pathway. On the other hand, the EMEA has considered these agents to be biosimilar. Furthermore, the EMEA stated that biosimilar versions of LMWHs should be considered biological medicinal products and may not be submitted for approval as generic medicinal products. In a concept guideline manuscript, the EMEA considers the heterogeneity of LMWH to be very high, and recommends clinical trials to demonstrate equivalence of biosimilar LMWHs [11]. Thus there is a regulatory discordance between the EMEA and US FDA.

As the biosimilar LMWHs have only recently been produced there is limited clinical data available with which to compare the biosimilar and branded versions. The available data from pharmacological in vitro or preclinical studies using anticoagulation profiles and neutralization with protamine sulfate as their primary outcomes differentiate branded from biosimilar LMWHs. Biosimilar and branded versions of enoxaparin [66,67] and dalteparin [67] differ in their responses to the inhibitor protamine sulfate, the composition of their oligosaccharide chains [66,67], their affinity for AT [67], and their immunogenic potential [68]. The differences in assay-responses become more pronounced at higher concentrations: for example, at prophylactic doses the anticoagulant levels of the branded and biosimilar enoxaparin appear similar but at treatment doses enoxaparin exhibits significantly greater anticoagulant effects [66]. Similar dose-dependent variations have been reported in the response to neutralization with protamine sulfate [67].

**Anticoagulants in development**

(Ultra-)LMWHs are currently being developed for different indications, amongst others bemiparin (Rovi, Madrid, Spain) and semuloparin (sonofi-aventis, Paris, France). Due to the clinical and practical limitations of warfarin, new oral anticoagulants to replace warfarin have also been sought. Oral vitamin K antagonists (warfarin) are used for long-term anticoagulation [6,7]. The first of the new oral anticoagulants was the oral direct thrombin inhibitor ximelagatran. However, this drug was withdrawn from use soon after it was licensed due to evidence of its potential hepatotoxicity. Two second-generation direct oral Factor Xa inhibitors—rivaroxaban, which has been approved in the EU and Canada, and apixaban—are currently in the final stages of clinical development. Based on the ximelagatran experience, clinical vigilance is required to determine the long-term safety of these agents. Dabigatran is another novel oral anticoagulant which has received recent approval in some European countries, Canada and recently in US; dabigatran is a direct thrombin inhibitor, administered orally as a double prodrug formulation (dabigatran etexilate). However, while this drug is approved in EMEA for post orthopedic surgical thromboprophylaxis, in the US, it is approved for stroke prevention in atrial fibrillation. Several other oral anticoagulants such as edoxaban, betrixiban are also in clinical development. A parenteral anti Xa agent with strong anticoagulant activity namely Otamixaban (sonofi-aventis, Paris, France) is also in advanced clinical stages as a parenteral anticoagulant in percutaneous intervention.

New anticoagulants completing clinical development are not supported by the depth of clinical evidence that is available for the currently recommended anticoagulants in terms of clinical experience or the range of patient populations and indications. Many issues remain to be elucidated, such as long-term safety, drug initiation, reversal of anticoagulation, and the appropriate bridging protocol from parenteral agents.

**Conclusions**

The use of antithrombotic agents in VTE management spans a continuum ranging from VTE prevention using prophylaxis of appropriate duration for at-risk patients to timely treatment of VTE. Ideally, an antithrombotic drug should have clinically proven efficacy with a good safety profile in both the prevention and treatment of VTE for a wide range of patient types. Each of the LMWHs is a distinct drug, with unique clinical pharmacokinetics and pharmacodynamics, and LMWHs cannot be prescribed interchangeably. LMWHs should be prescribed in accordance with recommended dose regimens for each licensed clinical indication, based on the
available clinical evidence for each agent. The newer parenteral anticoagulant, fondaparinux, is now also licensed for VTE prophylaxis in surgical patients and the treatment of acute DVT; clinical experience with this anticoagulant is expanding. In contrast to the LMWHs, fondaparinux does not exhibit polypharmacologic action although thrombosis is a polypathologic process. Generic versions of the branded LMWHs are now available for clinical use. However, because of the intra-class heterogeneity of LMWHs, each LMWH needs to be supported by clinical evidence of its efficacy and safety profile. Of the currently available antithrombotics, the LMWH enoxaparin offers the most extensive clinical experience and the widest range of clinical indications including surgical and medical thromboprophylaxis, and inpatient and outpatient treatment of VTE. Besides the LMWHs, several ultra-LMWHs are currently being developed for different indications. Therefore, this class of drug will continue to have a major impact in the future management of thrombosis. The newly developed oral antithrombin and anti-Xa agents are mono-therapeutic and will require clinical validation in specific indications.

Abbreviations
ACCP: American College of Chest Physicians; AT: antithrombin; bid: twice daily; CI: confidence interval; DVT: deep-vein thrombosis; EMEA: European Medicines Agency; FDA: Food and Drug Administration; IUA: International Union of Angiology; LMWH: low-molecular-weight heparin; PE: pulmonary embolism; RR: relative risk; tid: three times daily; UFH: unfractionated heparin; VTE: venous thromboembolism.

Acknowledgements
The authors received editorial/writing support in the preparation of this manuscript funded by sanofi-aventis U.S., Inc. Hester van Lier, PhD, provided the editorial/writing support. The authors were fully responsible for all content and editorial decisions and received no form of compensation related to the development of the manuscript. Dr. Cader Adiguzel was a fellow of the International Union of Angiology during the preparing of this manuscript. His fellowship was partially funded by the Turkish Society of Hematology.

Author details
1Departments of Pathology, Loyola University Medical Center, Maywood, Illinois, USA. 2Department of Pharmacology, Loyola University Medical Center, Maywood, Illinois, USA. 3Department of Medicine, Division of Hematology, Marmara University Medical School, Istanbul, Turkey. 4Department of Medicine, Aurora Memorial Hospital, Burlington, WI, USA.

Authors’ contributions
JF created the concept for the manuscript, drafted the manuscript, and approved the final manuscript. CA and IT critically revised the manuscript for important intellectual content and approved the final manuscript.

Competing interests
Professor Fareed has received research grants from Bayer Pharma, Germany, and Gentium, Italy, and has served as a symposium speaker for sanofi-aventis, France, and King Pharma, USA. Dr Adiguzel and Dr. Theghi report no conflict of interest.

Received: 13 October 2010 Accepted: 28 March 2011 Published: 28 March 2011

References
1. Heit JA, O’Fallon WM, Petterson TM, Lozhe OM, Silverstein MD, Mohr DN, Melton LJ: Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002, 162:1245-1248.
2. Anderson FA Jr, Zavarruzny M, Heit JA, Fidan D, Cohen AT: Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007, 82:777-782.
3. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007, 167:1471-1475.
4. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Am J Med 1996, 100:3484-3488.
5. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest 2008, 133(6 Suppl):381S-453S.
6. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, American College of Chest Physicians: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest 2008, 133(6 Suppl):454S-545S.
7. Cardiovascular Disease Educational and Research Trust, Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism. International Consensus Statement [guidelines according to scientific evidence], Int Angiol 2006, 25:101-161.
8. Nightingale SL. From the Food and Drug Administration. JAMA 1993, 270:1672.
9. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearl DL, Sloan MA, Smith SC Jr. 2004 Writing Committee Members, Aribe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tcheng J, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117:296-329.
10. Committee for Medicinal Products for Human Use (CHMP) [http://www.emea.europa.eu/ pdfs/human/biosimilar/11826407en.pdf].
11. World Health Organization [http://www.who.int/biologicalareas/biological_therapeutics/Final%20Biological%20Meetings%20Report%20for% 20web%20%20%20September%202007.pdf].
12. Kakkar V, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993, 341:259-265.
13. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. American College of Chest Physicians: Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):141S-159S.
14. Herbert JM, Héraut JP, Bernat A, van Amsterdam RG, Lorneau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentastacharide. Blood 1998, 91:4197-4205.

http://www.thrombosisjournal.com/content/9/1/5
16. Walenga JM, Jeske WP, Samama MW, Frapaise FX, Rick RL, Fareed J: Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002, 11:397-407.

17. Mismetti P, Laporte-Simardis S, Tardy B, Cucheat M, Buchmüller A, Juillard-Delsart D, Decousus H: Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000, 83:14-19.

18. Mismetti P, Laporte S, Darmon JV, Buchmüller A, Decousus H: Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001, 88:913-930.

19. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M: A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986, 315:925-929.

20. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc JR, Desjardins L, Laflamme GH, Lensing AW, Lassen MR, Bauer KA, Eriksson BI, Turpie AG, Steering Committee of the Pentasaccharide in Major Knee Surgery Study: Prevention of deep-vein thrombosis after elective hip replacement surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1999, 131:545-551.

21. Colwell CW Jr, Sprio TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, Comerota AJ, Skoutalakis VA: Use of enoxaparin, a low-molecular-weight heparin, and a comparison of unfractionated heparin for prevention of deep-vein thrombosis after elective hip replacement: a clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994, 76:3-14.

22. Colwell CW Jr, Callis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME: Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999, 81:922-940.

23. Hull RD, Pinoe GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmgvist A, Mant M, Dear R, Baylis B, Mah A, Brant R: Low molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000, 160:2199-2207.

24. Planès A, Samama MM, Lensing AW, Bick RL, Fareed J, Hardwick ME: Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999, 81:922-940.

25. Lassen MR, Bauer KA, Eriksson BI, Turpie AG, European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002, 359:1715-1720.

26. Turpie AG, Bauer KA, Eriksson BI, Lassen MR, PEGASUS investigators: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002, 359:1721-1726.

27. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L’Espedale B, Demers C, Kassis J, Cruchêkhan W, Trimman L, Delorme F: Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996, 124:619-626.

28. Fitzgerald RH Jr, Sprio TE, Trowbridge AA, Gardner GA Jr, Whitsett TL, O’Connell MB, O’hara JA, Young TR: Enoxaparin Clinical Trial Group: Prevention of venous thromboembolism following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001, 83-A:900-906.

29. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Major Knee Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001, 83-A:900-906.

30. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001, 345:1298-1304.

31. ENOXACAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997, 84:1099-1103.

32. Bergqvist D, Burenko RJ, Flordal PA, Frissell J, Hallbäck T, Hedberg M, Horn A, Kelby E, Kvitting P, Lindhagen A: Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 IU versus 5000 Xal units in 2070 patients. Br J Surg 1995, 82:496-501.

33. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS investigators: Randomized clinical trial of postoperative fondaparinux versus periprocedural enoxaparin for the prevention of venous thromboembolism in patients undergoing knee arthroplasty. A randomized, multicenter, open-label, parallel-group study. J Bone Joint Surg Am 2002, 84-A:1305-1310.

34. Turpie AG, Gallus AS, Gent M, Hirsh J, Carter CJ, Landon GC, Jové M, Enoxaparin Clinical Trial Group: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective hip replacement: a randomized, double-blind trial. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2002, 84-A:1305-1310.

35. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L’Espedale B, Demers C, Kassis J, Cruchêkhan W, Trimman L, Delorme F: Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996, 124:619-626.

36. Fitzgerald RH Jr, Sprio TE, Trowbridge AA, Gardner GA Jr, Whitsett TL, O’Connell MB, O’hara JA, Young TR: Enoxaparin Clinical Trial Group: Prevention of venous thromboembolism following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001, 83-A:900-906.

37. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Major Knee Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after knee arthroplasty. A randomized, multicenter, open-label, parallel group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001, 83-A:900-906.

38. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001, 345:1298-1304.

39. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L’Espedale B, Demers C, Kassis J, Cruchêkhan W, Trimman L, Delorme F: Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996, 124:619-626.

40. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Major Knee Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001, 83-A:900-906.
47. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skjekk Bro HP, Andersen G, Petersen AO, Siem P, Harlyck E, Jensen BV, Thomsen PB, Hansen BR, Enn-Madsen J, Møller JG, Rotwitt L, Christensen F, Nielsen JB, Jørgensen PS, Paaske B, Tørnholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Talve E. Efficacy and safety of prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) Study. *Thromb Res* 1998, 89:281-287.

48. Dahl OE, Andreaesen G, Aspelin T, Müller C, Mathiesen P, Nyhus S, Abdelmoor M, Solhaug JH, Arnesen H. Prolonged thromboprophylaxis following hip replacement surgery—results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (fragmin). *Thromb Haemost* 1997, 77:26-31.

49. Lausen I, Jensen R, Jørgensen LN, Rasmussen MS, Lyng KM, Andersen M, Raaschou HO, Wille-Jørgensen P. Incidence and prevention of deep venous thrombosis occurring late after general surgery; randomised controlled study of prolonged thromboprophylaxis. *Eur J Surg* 1999, 164:565-663.

50. Eriksson BI, Lassen MR, PENsaccharide in Hip Fracture Surgery Plus Matisse Investigators: Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. *Arch Intern Med* 2003, 163:1337-1342.

51. Singelyn FJ, Vehrenberg CC, Povella F, Van Aken HK, Rosencher N, Expert Study Investigators: for the Expert study investigators: The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the Expert Study. *Anesth Analg* 2007, 105:1540-1547.

52. Merli G, Spro T, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elas D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilka K. Enoxaparin Clinical Trial Group: Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. *Ann Intern Med* 2001, 134:191-202.

53. Lindmark P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. *Thromb Haemost* 1994, 72:186-190.

54. Fiesinger JN, Lopez-Fernandez M, Gattere E, Granqvist S, Kher A, Olsson CG, Soderberg K. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. *Thromb Haemost* 1996, 76:195-199.

55. Simmoneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Matisse Investigators: Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. *Thromb Haemost* 2004, 92:S10-16.

56. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Mismetti P, Quenet S, Levine M, Merli G, Decousus H, Derobert E, Laporte S. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. *Chest* 2005, 128:2203-2210.

57. Huse DM, Cummins G, Taylor DC, Russell MW. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation. *Am J Manag Care* 2002, 8(Supp L):S10-16.

58. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med* 2003, 349:146-153.

59. Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahl R, Bick RL. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. *Clin Appl Thromb Hemost* 2006, 12:267-276.

60. Jeske WP, Ackerman P, Drenth A, Walenga J, Bakhos M. Generic versions of branded low molecular weight heparins can be differentiated in biologic and pharmacologic assays [abstract]. *J Thromb Haemost* 2007, 5(Suppl 2):P-M-647.

61. Jeske WP, Brubaker A, Hoppensteadt D, Walenga JM, Ma Q, Fareed J. Differences in the oligosaccharide composition of generic versions of enoxaparin and dalteparin [abstract]. *J Thromb Haemost* 2007, 5(Suppl 2):P-M-670.

62. Fareed J, Bick RL, Rao G, Goldhaber SZ, Sasahara A, Messmore HL, Hoppensteadt DA, Nicolades IA, IACATH, IUAA, SAAT, NATF. The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products. *Clin Appl Thromb Hemost* 2008, 14:5-7.

Submit your next manuscript to BioMedCentral and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- You can post your manuscript as an online preprint before submission, for free
- Research which is freely available for redistribution

Cite this article as: Fareed et al: Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. *Thrombosis Journal* 2011, 9:5.